January 3, 2011 – A registered radiopharmaceutical product has received a positive opinion for the mutual recognition of the initial French authorization in 12 European Union concerned member states. The opinion concens IBA’s Dopacis (18F-Fluorodopa).

This is the final step in the application process before marketing authorizations are granted by the national health authorities of the EU concerned member states.

It is currently approved for use in France in positron emission tomography (PET) for indications in neurology and oncology. Specifically, it is used for the differential diagnosis of extrapyramidal symptoms linked to Parkinson’s disease and for diagnosing neuroendocrine tumors. PET is a non-invasive method used in molecular imaging to visualize biological processes for the early detection and real-time monitoring of diseases.

The company expects to obtain marketing approvals in the EU concerned member states in 2011.

For more information: www.iba-molecular.com


Additional Content

News | X-Ray

April 14, 2026 — KA Imaging is seeing continued adoption of its X-ray technology across new regions, with recent ...

Time April 15, 2026
arrow
News | Ultrasound Imaging

April 9, 2026 — GE HealthCare has announced a digital integration between the GE HealthCare bkActiv intraoperative ...

Time April 09, 2026
arrow
News | Teleradiology

April 1, 2026 — Premier Radiology Services has acquired Global Imaging Solutions (GLOBIS), a leading teleradiology group ...

Time April 03, 2026
arrow
News | Digital Pathology

March 29, 2026 — Leica Microsystems has introduced the Viventis SCAPE light sheet microscope. Viventis SCAPE enables ...

Time April 01, 2026
arrow
News | Digital Pathology

March 11, 2026 — Royal Philips has announced the expansion of its digital pathology portfolio with new cloud-enabled ...

Time March 26, 2026
arrow
Subscribe Now